An integrated analysis of data pooled from phase 2 and 3 trials supports the approved indication of glecaprevir/pibrentasvir (G/P) for hepatitis C virus (HCV) genotype 3 (GT 3) and confirms the efficacy of a shortened, eight-week duration of treatment in absence of cirrhosis.
Lead author of the analysis, Steven Flamm, MD, Northwestern Feinberg School of Medicine, Chicago, IL, explained to MD Magazine® that chronic HCV GT3 is common worldwide and that the prevalence in the US is increasing with the sharing of needles in the current opioid epidemic. He indicated that most of the infected individuals are treatment naïve and non-cirrhotic.
“Unfortunately, for unclear reasons, HCV GT3 is the most difficult to eradicate with direct acting antiviral (DAA) regimens,” Flamm explained. “G/P is the only regimen that has been approved to treat treatment naïve, non-cirrhotic patients for 8 weeks, yet there has been some trepidation regarding this short course for the difficult GT3 population.